Atovaquone/Proguanil Enfants Zentiva

Atovaquone/Proguanil Enfants Zentiva is a combination medication used to prevent and treat malaria. This oral medication is suitable for children and is manufactured by Laboratoire Glaxosmithkline.

Atovaquone/Proguanil Enfants Zentiva is primarily used for the prevention and treatment of malaria, a mosquito-borne disease caused by parasites. It is often prescribed for travelers to areas where malaria is common. The medication works by interfering with the growth of parasites in the red blood cells, helping to control and prevent the spread of the disease.

Common effects of Atovaquone/Proguanil Enfants Zentiva may include stomach pain, nausea, vomiting, and diarrhea. Some users might experience headache, dizziness, or cough. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare professional.

Atovaquone/Proguanil Enfants Zentiva should be used with caution in individuals with severe kidney disease or metabolic disorders. It is important to follow the prescribed dosage and complete the full course of treatment. Store the medication in a cool, dry place away from direct sunlight and keep it out of reach of children.

Atovaquone/Proguanil Enfants Zentiva may interact with certain medications, including those used to treat seizures, HIV, or tuberculosis. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol should be avoided while using this medication, as it may increase the risk of side effects.